IP Verse

Pharmaceutical Compositions Comprising Hydromorphone And Naloxone - EP2568967

The patent EP2568967 was granted to Euro Celtique on Jul 27, 2022. The application was originally filed on May 10, 2011 under application number EP11718747A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2568967

EURO CELTIQUE
Application Number
EP11718747A
Filing Date
May 10, 2011
Status
Patent Maintained As Amended
Jun 24, 2022
Grant Date
Jul 27, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

NEIDLEINJul 24, 2019GILLE HRABAL PARTNERSCHAFTSGESELLSCHAFT MBB PATENTANWALTE -
ALGOBATEJul 23, 2019TER MEER STEINMEISTER & PARTNER -

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4705695
EXAMINATIONEP1695700
EXAMINATIONUS4769372
EXAMINATIONUS6419959
INTERNATIONAL-SEARCH-REPORTUS2006039970
INTERNATIONAL-SEARCH-REPORTUS2007014732
INTERNATIONAL-SEARCH-REPORTUS4457933
INTERNATIONAL-SEARCH-REPORTWO03013525
INTERNATIONAL-SEARCH-REPORTWO2010140007
OPPOSITIONEP0271193
OPPOSITIONEP0352361
OPPOSITIONWO03084520
OPPOSITIONWO2010140007
OPPOSITIONWO2011141488

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- "Oxycodone / Naloxone Combination Tablet Reduces Opioid-induced Bowel Dysfunction In Patients With Chronic Severe Pain", INTERNET CITATION, (20070927), pages 1 - 2, URL: http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=83795, (20110505), XP002636068-
EXAMINATION- WIRZ S ET AL, "Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain", SUPPORTIVE CARE IN CANCER, SPRINGER-VERLAG, DE, (20071220), vol. 16, no. 9, ISSN 1433-7339, pages 999 - 1009, XP019632420-
OPPOSITION- "05 078 TARGIN 10/5 mg/-20/10 mg Retardtabletten", Rote Liste, (20090000), vol. 05, page 07 8, XP055626071-
OPPOSITION- "05 078 TARGIN 10/5 mg/-20/10 mg Retardtabletten", Rote Liste, (20090000), vol. 05, page 078, XP055626071-
OPPOSITION- "Arzneiverordnung in der Praxis", Tumorschmerzen, (20000000), vol. 2, pages 1 - 24, XP055626049-
OPPOSITION- "Bomarthros Harpagophytum", Rote Liste, (20090000), vol. 05, page 042, XP055626147-
OPPOSITION- "Bomarthros Harpagophytum", Rote Liste, (20090504), XP055626147-
OPPOSITION- "Hydromophone Hydrochloride Extendd Release Capsules", SmPC Palladon®, (20040000), pages 1 - 30, XP055626155-
OPPOSITION- "Hydromophone Hydrochloride Extendd Release Capsules", SmPC Palladone® retard, (20040000), XP055626155-
OPPOSITION- JUNKER et al., "Tumorschmerzen: Hoch differenzierte Opioidtherapie", Dtsch. Arztebl., (20080000), vol. 105, no. 8, XP055626056-
OPPOSITION- JUNKER et al., "Tumorschmerzen: Hoch differenzierte Opioidtherapie", Dtsch. Ärztebl., (20080000), vol. 105, no. 8, XP055626056-
OPPOSITION- Karzinomschmerz - Entstehung und Behandlung, ÄBW 01 2009-
OPPOSITION- "Kombipräparat verhindert Verstopfung bei Opioid-Therapie", Ärzte Zeitung, (20060802), pages 1 - 3, XP055626080-
OPPOSITION- Leyendecker, "Einfluss der gleichzeiten Applikation von Oxycodon und Naloxon auf Analgesie und oploid-induzierte gastrointestinale Dysfunktion", Dissertation, (20080000), pages 1 - 138, XP055626113-
OPPOSITION- "Naloxone SR Capsules in Patients With Opioid Constipation", Clinical Study: NCT00984334, (20100414), XP055626086-
OPPOSITION- "Optimisation of Hydromorphone - Naxolone Ratio for the Treatment of Pain", Clinical Study: NCT00992576, (20091000), XP055626073-
OPPOSITION- "Optimisation of Hydromorphone - Naxolone Ratio for the Treatment of Pain", Clinical Study: NCT00992576, (20091112), XP055626073-
OPPOSITION- Petra Leyendecker, "Einfluss der gleichzeiten Applikation von Oxycodon und Naloxon auf Analgesie und oploid-induzierte gastrointestinale Dysfunktion", Dissertation, (20080000), pages 1 - 138, XP055626113-
OPPOSITION- Roland Wörz, "Karzinomschmerz - Entstehung und Behandlung", Ärzteblatt, (20090100), page 21, 22, XP055626061-
OPPOSITION- "Tumorschmerzen", Arzneiverordnung in der Praxis, Tumorschmerzen, (20000000), vol. 2, pages 1 - 24, XP055626049-
OPPOSITION- "Veloron N retard 50/4 mg/-100/8 mg/-150/12 mg/-200/16 mg", Rote Liste, (20090000), vol. 05, page 13 8, XP055626166-
OPPOSITION- "Veloron N retard 50/4 mg/-100/8 mg/-150/12 mg/-200/16 mg", Rote Liste, (20090000), vol. 05, page 138, XP055626166-
OPPOSITION- ZENZ, JURNA, Lehrbuch der Schmerztherapie, (20010000), vol. 272, pages 462 - 463, XP055298289-
OPPOSITION- ZENZ, JURNA, Lehrbuch der Schmerztherapie, WVG, (20010000), vol. 272, pages 462 - 463, XP055298289-
OPPOSITION- MEISSNER et al., "A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation", European Journal of Pain, (20090000), vol. 13, doi:10.1016/j.ejpain.2008.06.012, pages 56 - 64, XP025865529

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents